Targets for Ibrutinib Beyond B Cell Malignancies

Ibrutinib (Imbruvica(™)) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Scand J Immunol
Main Authors: Berglöf, A., Hamasy, A., Meinke, S., Palma, M., Krstic, A., Månsson, R., Kimby, E., Österborg, A., Smith, C. I. E.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Reviews
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347933/
https://ncbi.nlm.nih.gov/pubmed/26111359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/sji.12333
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki